Skip to main content
letter
. 2022 Sep 15;12(9):e12189. doi: 10.1002/clt2.12189

FIGURE 2.

FIGURE 2

Correlation analyses for the three cohorts of severe asthma: non‐smoking severe asthma (NSA, N = 152), current‐smoking severe asthma (CSA, N = 16) and Ex‐smoking severe asthma (ESA, N = 39). The correlation analysis was performed for the whole group (“Corr”), followed by CSA (pink), ESA (green) and NSA (blue), using Spearman correlation analysis. The graphic relationship of these parameters are shown together with the actual correlations and their significance (*p < 0.05,**p < 0.01,***p < 0.001). The top row shows the median (25%–75% Interquartile range). EXA, Exacerbations in previous year; FENO, Fractional exhaled nitric oxide; FEV1%Pred, Pre‐bronchodilator FEV1%Predicted; FEV1/Forced Vital Capacity (FVC), Pre‐bronchodilator FEV1/FVC; FEV1IMPP, Post‐bronchodilator improvement in FEV1%Predicted; fNSA, female non‐smoking severe asthma; mNSA, male non‐smoking severe asthma; S_Eos_p, sputum eosinophil percentage; S_Lymph_p, sputum lymphocyte percentage; S_Macro_p, sputum macrophage percentage; S_Neu_p, sputum neutrophil percentage